JEANNE D PERELES-ORTIZ
- Type
- Physician · Allopathic & Osteopathic Physicians / Family Medicine
- Where
- COLSTRIP, MT
- NPI
- 1932174950
- Received
- $8,719 in 11 records, 2019 to 2021 ($7,024 general, $1,695 research)
- As principal investigator
- $70,814 of research payments to others in 26 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 2 | $2,890 |
| 2021 | Research payment | 1 | $858 |
| 2020 | General payment | 5 | $4,079 |
| 2020 | Research payment | 1 | $836 |
| 2019 | General payment | 2 | $54 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novo Nordisk Inc | 8 | $7,002 | 2019–2021 |
| Eli Lilly and Company | 2 | $1,695 | 2020–2021 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 5 | $6,936 |
| Research payment | 2 | $1,695 |
| Food and Beverage | 3 | $56 |
| Education | 1 | $32 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-09-30 | Novo Nordisk Inc | $867 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-04-12 | Eli Lilly and Company | $858 | Research payment | In-kind items and services | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2021 | |
| 2021-02-15 | Novo Nordisk Inc | $2,023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBELSUS Drug, Diabetes | 2021 | |
| 2020-10-05 | Novo Nordisk Inc | $289 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBELSUS Drug, Diabetes | 2020 | |
| 2020-05-20 | Eli Lilly and Company | $836 | Research payment | In-kind items and services | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2020 | |
| 2020-05-01 | Novo Nordisk Inc | $3,179 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ozempic Drug, Diabetes | 2020 | |
| 2020-05-01 | Novo Nordisk Inc | $578 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ozempic Drug, Diabetes | 2020 | |
| 2020-02-28 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Tresiba Drug, Diabetes | 2020 | |
| 2020-01-09 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Tresiba Drug, Diabetes | 2020 | |
| 2019-05-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-04-01 | Novo Nordisk Inc | $32 | Education | In-kind items and services | Victoza Drug, Diabetes | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2020-09-08 | SANOFI US SERVICES INC. | Billings Clinic | $3,606 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 |
| 2020-06-15 | SANOFI US SERVICES INC. | Billings Clinic | $3,056 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 |
| 2020-05-18 | SANOFI US SERVICES INC. | Billings Clinic | $1,756 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 |
| 2020-03-03 | SANOFI US SERVICES INC. | Billings Clinic | $3,512 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 |
| 2020-02-10 | SANOFI US SERVICES INC. | Billings Clinic | $3,137 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 |
| 2019-12-19 | Novo Nordisk AS | BILLINGS CLINIC | $4,541 | NN9924-4257 | 2019 |
| 2019-12-11 | SANOFI US SERVICES INC. | BILLINGS CLINIC | $1,756 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-11-25 | SANOFI US SERVICES INC. | BILLINGS CLINIC | $750 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-11-04 | SANOFI US SERVICES INC. | BILLINGS CLINIC | $2,575 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-09-23 | SANOFI US SERVICES INC. | BILLINGS CLINIC | $1,142 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-08-12 | SANOFI US SERVICES INC. | BILLINGS CLINIC | $1,100 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-07-02 | SANOFI US SERVICES INC. | BILLINGS CLINIC | $375 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-06-10 | SANOFI US SERVICES INC. | BILLINGS CLINIC | $2,200 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-04-30 | Novo Nordisk AS | BILLINGS CLINIC | $72 | NN9924-4257 | 2019 |
| 2019-03-29 | Novo Nordisk AS | BILLINGS CLINIC | $72 | NN9924-4257 | 2019 |
| 2019-03-26 | Novo Nordisk AS | BILLINGS CLINIC | $1,000 | NN9068-4228 | 2019 |
| 2019-03-26 | Novo Nordisk AS | BILLINGS CLINIC | $20,557 | NN9068-4228 | 2019 |
| 2019-02-28 | Novo Nordisk AS | BILLINGS CLINIC | $72 | NN9924-4257 | 2019 |
| 2019-02-21 | Novo Nordisk AS | BILLINGS CLINIC | $465 | NN9924-4257 | 2019 |
| 2019-01-31 | Novo Nordisk AS | BILLINGS CLINIC | $72 | NN9924-4257 | 2019 |
| 2019-01-28 | SANOFI US SERVICES INC. | BILLINGS CLINIC | $8,591 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-01-28 | SANOFI US SERVICES INC. | BILLINGS CLINIC | $550 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-01-28 | SANOFI US SERVICES INC. | BILLINGS CLINIC | $227 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-01-28 | SANOFI US SERVICES INC. | BILLINGS CLINIC | $3,426 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
| 2019-01-24 | Novo Nordisk AS | BILLINGS CLINIC | $899 | NN9924-4257 | 2019 |
| 2019-01-21 | SANOFI US SERVICES INC. | BILLINGS CLINIC | $5,300 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Colstrip, MT, county Rosebud County, MT, state Montana; placed by its city name.
| Measure | Place (city or town) Colstrip, MT | County Rosebud County, MT | State Montana |
|---|---|---|---|
| Population B01003 | 2,101 | 8,165 | 1,116,875 |
| Population, 2020 census P1 | 2,096 | 8,329 | 1,084,225 |
| Median age B01002 | 44.2 | 38.0 | 40.4 |
| Under 18 B01001 | 27.2% | 28.3% | 21.0% |
| 65 and over B01001 | 13.5% | 17.6% | 20.1% |
| Households B11001 | 802 | 3,070 | 458,859 |
| Foreign born B05002 | 0.6% | 2.3% | 2.3% |
| Median household income B19013 | $82,500 | $49,914 | $72,509 |
| Median family income B19113 | $120,313 | $69,853 | $92,794 |
| Per capita income B19301 | $42,447 | $29,231 | $41,711 |
| Poverty rate B17001 | 9.4% | 24.5% | 11.5% |
| Unemployment rate B23025 | 8.2% | 10.6% | 3.6% |
| Civilian labor force B23025 | 1,089 | 3,568 | 568,568 |
| Mean commute (minutes) B08013 | 10.7 | 15.5 | 19.1 |
| Bachelor's degree or higher B15003 | 25.9% | 20.9% | 35.2% |
| Housing units B25001 | 940 | 3,779 | 528,419 |
| Owner-occupied B25003 | 82.8% | 63.6% | 69.2% |
| Renters B25003 | 17.2% | 36.4% | 30.8% |
| Median home value B25077 | $194,900 | $182,400 | $375,800 |
| Median gross rent B25064 | $659 | $672 | $1,081 |
| White, not Hispanic B03002 | 67.7% | 51.4% | 83.6% |
| Black B03002 | 0.0% | 0.1% | 0.4% |
| Hispanic or Latino B03002 | 7.2% | 3.7% | 4.6% |
| Asian B03002 | 0.0% | 2.0% | 0.8% |
| American Indian and Alaska Native B03002 | 22.3% | 36.8% | 5.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Colstrip, MT.
Comments